Efficacy of Nivolumab for Head and Neck Cancer Patients with Primary Sites and Histological Subtypes Excluded from the CheckMate-141 Trial

Efficacy of Nivolumab for Head and Neck Cancer Patients with Primary Sites and Histological Subtypes Excluded from the CheckMate-141 Trial

Yasuyoshi Sato,1 Naoki Fukuda,1 Xiaofei Wang,1 Tetsuya Urasaki,1 Akihiro Ohmoto,1 Kenji Nakano,1 Mayu Yunokawa,1 Makiko Ono,1 Yukiko Sato,2 Hiroki Mitani,3 Junichi Tomomatsu,1 Shunji Takahashi1 1Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tok...

Full description

Bibliographic Details
Main Authors: Sato Y, Fukuda N, Wang X, Urasaki T, Ohmoto A, Nakano K, Yunokawa M, Ono M, Mitani H, Tomomatsu J, Takahashi S
Format: Article
Language:English
Published: Dove Medical Press 2020-06-01
Series:Cancer Management and Research
Subjects:
head and neck cancer
nivolumab
pd-1
immunotherapy
immune checkpoint inhibitor
checkmate-141
Online Access:https://www.dovepress.com/efficacy-of-nivolumab-for-head-and-neck-cancer-patients-with-primary-s-peer-reviewed-article-CMAR

Internet

https://www.dovepress.com/efficacy-of-nivolumab-for-head-and-neck-cancer-patients-with-primary-s-peer-reviewed-article-CMAR

Similar Items